Pair page
HGH with Insulin
Mechanism-tag overlap and published literature for HGH and Insulin, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
recombinant-human-growth-hormonerhgh
hormone
pancreatic-peptide-hormone
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying HGH and Insulin have published these mechanism-level observations. Not a co-administration recommendation.
Noted for completeness — the GH + insulin combination is widely cited in bodybuilding literature as the most potent anabolic stack and one of the most dangerous. GH is diabetogenic; insulin offsets GH-induced hyperglycemia but compounds hypoglycemia risk if dose is miscalculated. Multiple published bodybuilder fatalities involve this combination. Not recommended.
Quick facts
HGH
Insulin
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2007 | HGH | Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Garber AM, Hoffman AR. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146(2):104-115. PMID: 17200260. (The most-cited independent appraisal of anti-aging rhGH.) PMID 17200260 | systematic review |
| 2020 | HGH | Johannsson G, Gordon MB, Højby Rasmussen M, Håkonsson IH, Karges W, Sværke C, Tahara S, Takano K, Biller BMK. Once-weekly somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial. J Clin Endocrinol Metab. 2020;105(4):e1358-e1376. PMID:… PMID 32072187 | human trial, Phase 3 |
| 2000 | HGH | Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J; Genentech, Inc Cooperative Study Group. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. J Clin Endocrinol Metab. 2000… PMID 11061517 | human trial |
| 2012 | HGH | Sävendahl L, Maes M, Albertsson-Wikland K, Borgström B, Carel JC, Henrard S, Speybroeck N, Thomas M, Zandwijken G, Hokken-Koelega A. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium… PMID 22259051 | human study |
| 2011 | HGH | Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML; Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(6):1587-1609. PMID: 21543432. PMID 21543432 | human study |
| 2003 | HGH | Grinspoon S, Mulligan K; Department of Health and Human Services Working Group on the Prevention and Treatment of Wasting and Weight Loss. Weight loss and wasting in patients infected with human immunodeficiency virus. Clin Infect Dis. 2003;36(Suppl 2):S69-S78. PMID: 12652374. (… PMID 12652374 | human study |
| 1990 | HGH | Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990;323(1):1-6. PMID: 2355952. (The landmark anti-aging reference.) PMID 2355952 | human study |
| 2026 | HGH | WADA. 2026 World Anti-Doping Code Prohibited List. Section S2 — Peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency. (rhGH S2 prohibition and detection methods.) | regulatory / registry |
| 2021 | HGH | U.S. Food and Drug Administration. Skytrofa (lonapegsomatropin-tcgd) Prescribing Information. Ascendis Pharma. First approved 2021. | regulatory / registry |
| 2020 | HGH | U.S. Food and Drug Administration. Sogroya (somapacitan) Prescribing Information. Novo Nordisk. First approved 2020. | regulatory / registry |
| — | HGH | U.S. Food and Drug Administration. Genotropin (somatropin) Prescribing Information. Pfizer Inc. | regulatory / registry |
| — | HGH | U.S. Food and Drug Administration. Norditropin (somatropin) Prescribing Information. Novo Nordisk Inc. | regulatory / registry |
| 2003 | Insulin | Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080-3086. PMID: 14578243. PMID 14578243 | human trial |
| 1998 | Insulin | UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853. PMID: 9742976. PMID 9742976 | human study |
| 1997 | Insulin | Anderson JH Jr, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes. 1997;46(2):265-270. PMID: 9000704. PMID 9000704 | human study |
| 1993 | Insulin | The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986. PMID: 8366922. PMID 8366922 | human study |
| — | Insulin | Banting FG, investigated CH. The internal secretion of the pancreas. J Lab Clin Med. 1922;7(5):251-266. (Foundational discovery of insulin.) | mechanism / discovery |
| 2026 | Insulin | World Anti-Doping Agency. 2026 Prohibited List — Section S4: Hormone and Metabolic Modulators. wada-ama.org. | regulatory / registry |
| — | Insulin | U.S. Food and Drug Administration. Humulin, Humalog, Novolog, Lantus, Toujeo, Levemir, Tresiba prescribing information. FDA.gov. | regulatory / registry |
| 2020 | Insulin | Garber AJ, Handelsman Y, Grunberger G, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm — 2020 executive summary. Endocr Pract. 2020;26(1):107-139.… PMID 32022600 | research article |
| 2017 | Insulin | Marso SP, McGuire DK, Zinman B, et al; DEVOTE Study Group. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017;377(8):723-732. PMID: 28605603. PMID 28605603 | research article |
| 2012 | Insulin | Gerstein HC, Bosch J, Dagenais GR, et al; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319-328. PMID: 22686416. PMID 22686416 | research article |
| 2009 | Insulin | Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Insulin as an anti-inflammatory and antiatherogenic modulator. J Am Coll Cardiol. 2009;53(5 Suppl):S14-S20. PMID: 19179212. PMID 19179212 | research article |
| 2008 | Insulin | Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589. PMID: 18784090. (UKPDS legacy follow-up.) PMID 18784090 | research article |
Related pair pages
More research context
Frequently asked
Have HGH and Insulin been studied together?
Researchers have published mechanistic-level co-administration discussion of HGH and Insulin. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do HGH and Insulin share?
HGH and Insulin share these mechanism tags on their Kalios profiles: hormone. Tags are descriptive and verbatim from each compound profile — not an inference of combined effect.
What is the FDA status of HGH and Insulin?
HGH: Approved (GHD, Turner, PWS, SHOX, ISS, CKD, AIDS wasting, SBS). Insulin: Approved (1923 animal; 1982 rDNA). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on HGH and Insulin?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the HGH profile and the Insulin profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026